ReviewBMC nephrology2025
Exploring the role of pentoxifylline as a renal protector in diabetic kidney disease: a comprehensive review.
Review in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Short- and Middle-Term Nephroprotective and Cardioprotective Effects of Pentoxifylline in Patients with Diabetic Nephropathy: A Randomized Controlled Trial.Medical sciences (Basel, Switzerland) · 2026Trial
- Decoding fibroblast activation: Transcriptional networks in hepatic stellate cells and across fibrotic organs (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic Kidney Disease (DKD) is a leading cause of chronic kidney disease and end-stage renal disease, significantly impacting global public health. Despite the availability of conventional treatments like renin-angiotensin system (RAAS) inhibitors, disease progression remains a challenge. Pentoxifylline, an anti-inflammatory and immunomodulatory agent, has emerged as a promising adjunctive therapy for DKD. This review explores pentoxifylline's mechanisms of action, including its effects on inflammation, oxidative stress, fibrosis, and renal function, supported by clinical and preclinical evidence. Studies indicate that pentoxifylline can reduce proteinuria, improve glomerular filtration rate, and protect against kidney fibrosis in DKD, offering a multifaceted approach to disease management. By addressing several key pathways in DKD progression, pentoxifylline may provide an essential addition to existing therapeutic strategies, especially in patients with advanced disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.